Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Corticosteroid therapy for pneumonia – Author’s reply

Ar Kar Aung and colleagues state that the slow rate of inclusion in our study1 could have resulted in a selection of patients with mild community-acquired pneumonia (CAP). A slow rate of inclusion is a common and expected problem in randomised controlled trials (RCTs) using corticosteroids.2 To limit potential selection of patients with mild CAP, we had ethics committee approval to include patients with temporary inability for informed consent because of severe disease with consent of next of kin, assuring that the most severe cases were also included.